Antithrombotic therapy in atrial fibrillation

Hart RG , Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688–95

National Sentinel Clinical Audit. Evidence Based Prescribing for Older People. Report of National Results. London: Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, 1999

Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1999; 154: 1449–57

Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91

Hart RG , Benavente O. Primary prevention of stroke in patients with atrial fibrillation. Consensus conference. Proc R Coll Physicians Edinb 1999; (suppl 6):20–6

Feinberg WM , Cornell ES , Nightingale SD Relationship between prothrombin activation fragment F1,2 and international normalised ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997; 28: 1101–16

Lip GYH. Thromboprophylaxis for atrial fibrillation. Lancet 1999; 353: 4–5

Hart RG , Pearce LA , Rothbart RM , McAnulty JH , Asinger RW , Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. JACC 2000; 35: 183–7

Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1997; 349: 1565–6